JP2019526556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526556A5 JP2019526556A5 JP2019509552A JP2019509552A JP2019526556A5 JP 2019526556 A5 JP2019526556 A5 JP 2019526556A5 JP 2019509552 A JP2019509552 A JP 2019509552A JP 2019509552 A JP2019509552 A JP 2019509552A JP 2019526556 A5 JP2019526556 A5 JP 2019526556A5
- Authority
- JP
- Japan
- Prior art keywords
- isrna
- guanosine
- guanine
- uracil
- uridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 26
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 24
- 206010028980 Neoplasm Diseases 0.000 claims 20
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 13
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 13
- 229940045145 uridine Drugs 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- VTIYIXJVHDMAGD-GWTDSMLYSA-N 2-amino-3,7-dihydropurin-6-one;2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound O=C1NC(N)=NC2=C1NC=N2.C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VTIYIXJVHDMAGD-GWTDSMLYSA-N 0.000 claims 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 229940035893 uracil Drugs 0.000 claims 11
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 10
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 208000030381 cutaneous melanoma Diseases 0.000 claims 10
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 10
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 10
- 201000003708 skin melanoma Diseases 0.000 claims 10
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 9
- 125000002091 cationic group Chemical group 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 239000002777 nucleoside Substances 0.000 claims 7
- 125000003835 nucleoside group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229930024421 Adenine Natural products 0.000 claims 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 6
- 206010039491 Sarcoma Diseases 0.000 claims 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 6
- 229960000643 adenine Drugs 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 5
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims 5
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 5
- 206010042971 T-cell lymphoma Diseases 0.000 claims 5
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 5
- 229940104302 cytosine Drugs 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 229940029575 guanosine Drugs 0.000 claims 5
- 201000005962 mycosis fungoides Diseases 0.000 claims 5
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 5
- 238000011301 standard therapy Methods 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 3
- 102000015636 Oligopeptides Human genes 0.000 claims 3
- 108010038807 Oligopeptides Proteins 0.000 claims 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 3
- 210000004392 genitalia Anatomy 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 229940104230 thymidine Drugs 0.000 claims 3
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 claims 2
- 244000137850 Marrubium vulgare Species 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- SKRDOEKPLGTFEY-IAIGYFSYSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione;1h-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SKRDOEKPLGTFEY-IAIGYFSYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 1
- 241000321096 Adenoides Species 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- 229940125563 LAG3 inhibitor Drugs 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 229940125555 TIGIT inhibitor Drugs 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 210000002534 adenoid Anatomy 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 150000001945 cysteines Chemical group 0.000 claims 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091027963 non-coding RNA Proteins 0.000 claims 1
- 102000042567 non-coding RNA Human genes 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2016/069753 | 2016-08-19 | ||
| EP2016069753 | 2016-08-19 | ||
| EP2017064463 | 2017-06-13 | ||
| EPPCT/EP2017/064463 | 2017-06-13 | ||
| PCT/EP2017/025230 WO2018033254A2 (en) | 2016-08-19 | 2017-08-14 | Rna for cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526556A JP2019526556A (ja) | 2019-09-19 |
| JP2019526556A5 true JP2019526556A5 (enExample) | 2020-09-24 |
Family
ID=59772586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019509552A Pending JP2019526556A (ja) | 2016-08-19 | 2017-08-14 | 癌治療用ｒｎａ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190185859A1 (enExample) |
| EP (1) | EP3500295A2 (enExample) |
| JP (1) | JP2019526556A (enExample) |
| KR (1) | KR20190039969A (enExample) |
| CN (1) | CN109715205A (enExample) |
| AU (1) | AU2017314067A1 (enExample) |
| BR (1) | BR112019000598A2 (enExample) |
| CA (1) | CA3025812A1 (enExample) |
| MX (1) | MX2019001920A (enExample) |
| SG (2) | SG11201811432WA (enExample) |
| WO (1) | WO2018033254A2 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| SG11201506052PA (en) * | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
| EP4023755B1 (en) | 2014-12-12 | 2023-04-26 | CureVac SE | Artificial nucleic acid molecules for improved protein expression |
| WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
| DK3303583T3 (da) | 2015-05-29 | 2020-07-13 | Curevac Real Estate Gmbh | Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering |
| WO2017064146A1 (en) | 2015-10-12 | 2017-04-20 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| PT3319587T (pt) | 2015-11-17 | 2019-11-20 | Bioncotech Therapeutics S L | Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina |
| WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
| EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| US12612654B2 (en) | 2016-02-12 | 2026-04-28 | CureVac SE | Method for analyzing RNA |
| WO2017140905A1 (en) | 2016-02-17 | 2017-08-24 | Curevac Ag | Zika virus vaccine |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| EP4631970A3 (en) | 2016-05-04 | 2026-01-07 | CureVac SE | Nucleic acid molecules and uses thereof |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| PL3458083T3 (pl) | 2016-05-18 | 2023-03-13 | Modernatx, Inc. | Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania |
| WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
| WO2018104538A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rna for treatment or prophylaxis of a liver disease |
| WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
| WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| WO2018155716A1 (ja) * | 2017-02-27 | 2018-08-30 | 丸市倉庫株式会社 | 情報処理装置 |
| KR20240144261A (ko) | 2017-02-28 | 2024-10-02 | 사노피 | 치료적 rna |
| MX2019011215A (es) | 2017-03-24 | 2020-02-12 | Curevac Ag | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. |
| US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| KR20190141695A (ko) | 2017-04-13 | 2019-12-24 | 센티 바이오사이언시스, 인코포레이티드 | 병용 암 면역요법 |
| EP3625363A1 (en) | 2017-05-17 | 2020-03-25 | CureVac Real Estate GmbH | Method for determining at least one quality parameter of an rna sample |
| JP2020520368A (ja) | 2017-05-17 | 2020-07-09 | ビオンコテック セラピューティクス エセ．エレ | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| JP7722629B2 (ja) | 2017-07-04 | 2025-08-13 | キュアバック エスイー | 新規核酸分子 |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| SG11202003247RA (en) | 2017-11-08 | 2020-05-28 | Curevac Ag | Rna sequence adaptation |
| US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
| CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
| EP3773702A2 (en) * | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| GB201807944D0 (en) * | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Compositions and methods for haematopoietic stem cell transplantation |
| EP3810151B1 (en) * | 2018-06-20 | 2025-08-06 | Yale University | Rig-i agonists and treatments using same |
| CA3102135A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| CA3116138A1 (en) | 2018-10-17 | 2020-04-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| WO2020131656A1 (en) * | 2018-12-17 | 2020-06-25 | Immune Design Corp. | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer |
| CA3122645A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| GB201900702D0 (en) | 2019-01-18 | 2019-03-06 | Univ Bristol | Therapy |
| AU2020210614A1 (en) * | 2019-01-21 | 2021-08-26 | Sanofi | Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers |
| CN110373351B (zh) * | 2019-07-09 | 2021-02-02 | 华中农业大学 | 一种冻干保护剂及其在制备乳酸菌冻干粉中应用 |
| WO2021028439A1 (en) * | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
| US20220387555A1 (en) * | 2019-11-14 | 2022-12-08 | Ludwig Institute For Cancer Research Ltd | Compositions and methods for immunotherapy |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| CA3162019A1 (en) | 2019-12-20 | 2021-06-24 | Gemma NAVARRO | Lipid nanoparticles for delivery of nucleic acids |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| GB202009039D0 (en) | 2020-06-15 | 2020-07-29 | Univ Bristol | Therapy |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| KR20230129479A (ko) * | 2021-01-08 | 2023-09-08 | 스트랜드 세러퓨틱스 인코포레이티드 | 발현 구성체 및 이의 용도 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| KR102938028B1 (ko) * | 2022-11-11 | 2026-03-13 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| TW202440909A (zh) * | 2022-12-20 | 2024-10-16 | 美商健生生物科技公司 | 溶瘤病毒及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US5759546A (en) | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US5534499A (en) | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| ATE492644T1 (de) | 1999-09-09 | 2011-01-15 | Curevac Gmbh | Transfer von mrna unter verwendung von polykationischen verbindungen |
| EP1248654B1 (en) * | 2000-01-20 | 2005-10-05 | Universität Zürich Institut für Medizinische Virologie | Intra-tumoral administration of il-12 encoding naked nucleic acid molecules |
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| NZ535952A (en) * | 2002-04-04 | 2009-01-31 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US8153773B2 (en) | 2007-06-19 | 2012-04-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| JP5721441B2 (ja) * | 2008-01-31 | 2015-05-20 | キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ | 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体 |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| EP3699172A3 (en) | 2008-11-10 | 2020-11-18 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| EP2391343B1 (en) | 2009-01-29 | 2017-03-01 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
| CA3042927C (en) | 2009-05-05 | 2022-05-17 | Arbutus Biopharma Corporation | Lipid compositions for the delivery of therapeutic agents |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| CN104922071A (zh) | 2010-04-09 | 2015-09-23 | 帕西拉制药有限公司 | 用于配制大直径合成膜囊泡的方法 |
| EP4481047A3 (en) | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム |
| RS63890B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| CN103261217B (zh) | 2010-11-11 | 2017-04-26 | 港大科桥有限公司 | 可溶性 pd‑1变体、融合构建体及其用途 |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2013059475A1 (en) | 2011-10-18 | 2013-04-25 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
| WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| ES2660129T3 (es) | 2012-03-27 | 2018-03-20 | Curevac Ag | Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP |
| SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| JP7060324B2 (ja) * | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| WO2015149944A2 (en) * | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| BR112017009835A2 (pt) | 2014-12-30 | 2017-12-26 | Curevac Ag | moléculas de ácido nucleico artificiais |
| AU2016251687C1 (en) * | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| US12258567B2 (en) | 2015-08-28 | 2025-03-25 | CureVac SE | Artificial nucleic acid molecules |
| EP3374504B1 (en) | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
-
2017
- 2017-08-14 CN CN201780050519.2A patent/CN109715205A/zh active Pending
- 2017-08-14 SG SG11201811432WA patent/SG11201811432WA/en unknown
- 2017-08-14 MX MX2019001920A patent/MX2019001920A/es unknown
- 2017-08-14 SG SG10201913631TA patent/SG10201913631TA/en unknown
- 2017-08-14 AU AU2017314067A patent/AU2017314067A1/en not_active Abandoned
- 2017-08-14 CA CA3025812A patent/CA3025812A1/en active Pending
- 2017-08-14 BR BR112019000598-6A patent/BR112019000598A2/pt not_active IP Right Cessation
- 2017-08-14 EP EP17761442.7A patent/EP3500295A2/en not_active Withdrawn
- 2017-08-14 WO PCT/EP2017/025230 patent/WO2018033254A2/en not_active Ceased
- 2017-08-14 US US16/326,281 patent/US20190185859A1/en not_active Abandoned
- 2017-08-14 JP JP2019509552A patent/JP2019526556A/ja active Pending
- 2017-08-14 KR KR1020197006203A patent/KR20190039969A/ko not_active Ceased
-
2022
- 2022-01-10 US US17/571,893 patent/US20220396796A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kudarha et al. | Albumin based versatile multifunctional nanocarriers for cancer therapy: Fabrication, surface modification, multimodal therapeutics and imaging approaches | |
| Ibraheem et al. | Administration strategies for proteins and peptides | |
| Schmidt et al. | Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703 | |
| JP2018530560A5 (enExample) | ||
| JP2014532649A5 (enExample) | ||
| JP2020521445A5 (enExample) | ||
| CN110168088A (zh) | 抑制cd73表达的免疫抑制恢复寡核苷酸 | |
| WO2017162055A1 (zh) | 环二核苷酸cGAMP-脂质体在抗肿瘤中的应用 | |
| JP2002515445A (ja) | 細胞毒性活性を有する医薬品調製のためのｈｍｇ蛋白質の使用 | |
| JP2023536466A5 (enExample) | ||
| JP2017516462A5 (enExample) | ||
| IL321667A (en) | Exon skipping oligomer conjugates for muscular dystrophy | |
| JP2011500011A (ja) | 癌治療用の組合せ製品 | |
| CN115636868A (zh) | 一种基于阳离子纳米载体的多肽递送系统及其制备方法和用途 | |
| Zhou et al. | A novel systemic siDR6 delivery system based on DP7-C for the treatment of metastatic lung cancer | |
| CN101346137A (zh) | 含有孔布勒塔斯塔坦与抗癌剂的组合物 | |
| CN116077673A (zh) | 一种f碱基白蛋白药物运载体系及其制备方法和用途 | |
| JP6987271B2 (ja) | 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途 | |
| JP2023546383A5 (enExample) | ||
| CN101642462B (zh) | 一种肿瘤抑制剂nrn1sr42 | |
| Shen | Development of Polymer-assisted Compaction of DNA Nanoparticles for Cancer Treatment. | |
| CN118717814A (zh) | 一种治疗肺癌的联合用药物组合物及其应用 | |
| CN101643729B (zh) | 核酸分子nrn1sr22及其在制备抗癌药物中的应用 | |
| CN101642463A (zh) | 一种肿瘤抑制剂nrn1sr4 | |
| JP2010526776A5 (enExample) |